Premium
Lenalidomide in combination with R‐ ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: a phase 1b study from GELTAMO group
Author(s) -
Martín Alejandro,
Redondo Alba M.,
Dlouhy Iván,
Salar Antonio,
GonzálezBarca Eva,
Canales Miguel,
MontesMoreno Santiago,
Ocio Enrique M.,
LópezGuillermo Armando,
Caballero Dolores
Publication year - 2016
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13945
Subject(s) - lenalidomide , medicine , etoposide , cytarabine , gastroenterology , rituximab , regimen , multiple myeloma , autologous stem cell transplantation , diffuse large b cell lymphoma , oncology , surgery , chemotherapy , lymphoma
Summary Diffuse large B‐cell lymphoma ( DLBCL ) patients failing rituximab‐containing therapy have a poor outcome with the current salvage regimens. We conducted a phase 1b trial to determine the maximum tolerated dose ( MTD ) of lenalidomide in combination with R‐ ESHAP (rituximab, etoposide, cisplatin, cytarabine, methylprednisolone) ( LR ‐ ESHAP ) in patients with relapsed or refractory DLBCL . Efficacy data were collected as a secondary objective. Subjects received 3 cycles of lenalidomide at escalating doses (5, 10 or 15 mg) given on days 1–14 of every 21‐day cycle, in combination with R‐ ESHAP . Responding patients received BEAM (carmustine, etoposide, cytarabine, melphalan) followed by autologous stem‐cell transplantation. Lenalidomide 10 mg/d was identified as the MTD because, in the 15 mg cohort, one patient experienced dose‐limiting toxicity (grade 3 angioedema) and two patients had mobilization failure. A total of 19 patients (3, 12 and 4 in the 5, 10 and 15 mg cohorts, respectively) were evaluable. All toxicities occurring during LR ‐ ESHAP cycles resolved appropriately and no grade 4–5 non‐haematological toxicities were observed. The complete remission and overall response rates were 47·4% and 78·9%, respectively. With a median follow‐up of 24·6 (17·4–38·2) months, the 2‐year progression‐free survival and overall survival were 44% and 63%, respectively. In conclusion, the LR ‐ ESHAP regimen is feasible and yields encouraging outcomes.